The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s immunosuppressants market report forecasts the immunosuppressants market size to grow to $38.35 Billion by 2027, with a CAGR (compound annual growth rate) of more than 14%.

Learn More On The Immunosuppressants Market Report 2023 – https://www.thebusinessresearchcompany.com/report/immunosuppressant-global-market-report

Immunosuppressants Market Size Forecast

The global immunosuppressants market is expected to grow from $19.52 billion in 2022 to $22.59 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The immunosuppressants market is expected to grow from $38.35 billion in 2027 at a CAGR of 14.1%.

North America held the largest immunosuppressants market share.

Key Immunosuppressants Market Driver ­– Rise In Incidences Of Organ Failure

For instance, in June 2020, according to the United Network for Organ Sharing (UNOS), a US-based scientific and educational organization, 39,718 organ transplants were performed in the United States. Furthermore, according to the American Kidney Fund, a US-based health organization, on the national transplant waiting list in June 2022, there will be more than 106,000 people, of whom 92,000 (or 87%) are waiting for a kidney transplant in the US. The increasing number of cases of organ transplants and incidences of organ failure in patients is therefore expected to drive market growth.

Request for A Sample Of The Global Immunosuppressants Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3467&type=smp

Key Immunosuppressants Market Trend – Launching Phenotypic Personalised Medicine

Phenotypic personalised medicine or PPM or a hybrid of artificial intelligence and physician intervention is a new approach to overcoming the issues with immunosuppressants. For instance, tacrolimus is the most widely used immunosuppressant for patients who are undergoing organ transplantation. When the patient is in the hospital, Tacrolimus immunosuppressant levels must be checked regularly and changed frequently. A PPM approach that is based on a computational platform is used to overcome this concern. The inputs from the computational platform-based PPM approach include the past response of the patient to the dose of the drug and other drugs that are being taken, as well as current data on the liver and kidney. Using PPM, the physician can identify the optimal drug and dose combination from various possibilities. Therefore, it is believed that artificial intelligence is leading the way to not only more personalised and effective drug dosing but also enhancing physicians’ decision-making capabilities by providing clinical data rather than predicted responses.

Immunosuppressants Market Segment

1) By Drug Class: Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Other Drug Classes

2) By Indication: Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Immunosuppressants Market Major Players and Strategies

Major players in the immunosuppressants market are Astellas Pharma, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Intas Pharmaceuticals Ltd., Mylan Laboratories Inc., Pfizer, Novartis, Novartis AG, and Sanofi S.A.

In October 2022, Amgen Inc., a US-based biopharmaceutical and biotechnology company, acquired ChemoCentryx Inc. for $3.7 billion. Through this acquisition, Amgen increases its inflammation and nephrology drug product portfolio and has three therapeutic candidates in the early stages that target chemoattractant receptors, additional inflammatory conditions, and an oral cancer checkpoint. ChemoCentryx, Inc. is a US-based biopharmaceutical company pioneering in the development and commercialization of novel drugs for cancer, autoimmune, and inflammatory illnesses.

The Immunosuppressants Global Market Report 2023 covers regional data on immunosuppressants market size, immunosuppressants market trends and drivers, opportunities, strategies, and immunosuppressants market competitor analysis. The countries covered in the immunosuppressants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Immunosuppressant refers to a medication that prevents the immune system from attacking healthy cells and tissues. These medications are used to stop transplant rejection in recipients of stem cell and organ transplants. The medications also address the symptoms of autoimmune diseases. Immunosuppressants are potent medications that need to be carefully monitored to prevent side effects.

View More Reports Related To The Immunosuppressants Market –

Multiple Sclerosis Drugs Global Market Report 2023

AntiHypertensive Drugs Global Market Report 2023

Antibody Drug Conjugates Global Market Report 2023

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: